Periodontol 2000. 2014 Oct;66(1):59-71. doi: 10.1111/prd.12043.
A transalveolar approach for sinus floor elevation with subsequent placement of dental implants was first suggested by Tatum in 1986. In 1994, Summers described a different transalveolar approach using a set of tapered osteotomes with increasing diameters. The transalveolar approach of sinus floor elevation, also referred to as 'osteotome sinus floor elevation', the 'Summers technique' or the 'Crestal approach', may be considered as being more conservative and less invasive than the conventional lateral window approach. This is reflected by the fact that more than nine out of 10 patients who experienced the surgical procedure would be willing to undergo it again. The main indication for transalveolar sinus floor elevation is reduced residual bone height, which does not allow standard implant placement. Contraindications for transalveolar sinus floor elevation may be intra-oral, local or medical. The surgical approach utilized over the last two decades is the technique described by Summers, with or without minor modifications. The surgical care after implant placement using the osteotome technique is similar to the surgical care after standard implant placement. The patients are usually advised to take antibiotic prophylaxis and to utilize antiseptic rinses. The main complications reported after performing a transalveolar sinus floor elevation were perforation of the Schneiderian membrane in 3.8% of patients and postoperative infections in 0.8% of patients. Other complications reported were postoperative hemorrhage, nasal bleeding, blocked nose, hematomas and benign paroxysmal positional vertigo. Whether it is necessary to use grafting material to maintain space for new bone formation after elevating the sinus membrane utilizing the osteotome technique is still controversial. Positive outcomes have been reported with and without using grafting material. A prospective study, evaluating both approaches, concluded that significantly more bone gain was seen when grafting material was used (4.1 mm mean bone gain compared with 1.7 mm when no grafting material was utilized). In a systematic review, including 19 studies reporting on 4388 implants inserted using the transalveolar sinus floor elevation technique, the 3-year implant survival rate was 92.8% (95% confidence interval: 87.4-96.0%). Furthermore, a subject-based analysis of the same material revealed an annual failure rate of 3.7%. Hence, one in 10 subjects experienced implant loss over 3 years. Several of the included studies demonstrated that transalveolar sinus floor elevation was most predictable when the residual alveolar bone height was ≥ 5 mm and the sinus floor anatomy was relatively flat.
1986 年,塔图姆首次提出了经牙槽骨切开术提升窦底并随后植入牙种植体的方法。1994 年,萨默斯(Summers)描述了一种不同的经牙槽骨切开术,使用一组直径逐渐增大的锥形骨凿。经牙槽骨窦底提升术,也称为“骨凿窦底提升术”、“萨默斯技术”或“嵴顶入路”,与传统的外侧开窗术相比,可能被认为更保守、侵入性更小。这一点从以下事实可以看出:超过十分之九的接受过手术的患者表示愿意再次接受手术。经牙槽骨窦底提升的主要适应证是剩余骨高度不足,不允许标准植入物放置。经牙槽骨窦底提升的禁忌证可能是口内、局部或医学方面的。过去二十年中使用的手术方法是萨默斯(Summers)描述的技术,可进行或不进行微小修改。使用骨凿技术植入种植体后的手术护理与标准植入体植入后的手术护理相似。患者通常被建议进行抗生素预防和使用抗菌漱口水。经牙槽骨窦底提升后报告的主要并发症是 3.8%的患者出现了施莱希膜穿孔,0.8%的患者出现了术后感染。其他报告的并发症包括术后出血、鼻出血、鼻塞、血肿和良性阵发性位置性眩晕。在使用骨凿技术提升窦膜后,是否需要使用移植物材料来维持新骨形成的空间仍然存在争议。有报道称,使用和不使用移植物材料都有积极的结果。一项前瞻性研究评估了这两种方法,得出的结论是,使用移植物材料时,骨量增加更为明显(平均骨量增加 4.1 毫米,而不使用移植物材料时为 1.7 毫米)。在一项包括 19 项研究、报告了 4388 例使用经牙槽骨窦底提升技术植入的种植体的系统评价中,3 年种植体存活率为 92.8%(95%置信区间:87.4-96.0%)。此外,对同一材料的基于受试者的分析显示,年失败率为 3.7%。因此,在 3 年内,每 10 名受试者中就有 1 名发生种植体丢失。纳入的多项研究表明,当剩余牙槽骨高度≥5 毫米且窦底解剖结构相对平坦时,经牙槽骨窦底提升术最具可预测性。